Ken Griffin Infinity Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.16 - $0.74 $62,927 - $291,039	393,296 New	393,296 $62,000
Q2 2022 Aug 15, 2022	BUY	$0.49 - $1.2 $156,112 - $382,315	318,596 Added 308.4%	421,901 $267,000
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $93,839 - $264,957	-110,399 Reduced 51.66%	103,305 $117,000
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $52,197 - $94,291	-28,063 Reduced 11.61%	213,704 $480,000
Q3 2021 Nov 15, 2021	BUY	$1.52 - $3.82 $245,510 - $617,006	161,520 Added 201.28%	241,767 $827,000
Q2 2021 Aug 16, 2021	SELL	$2.66 - $3.47 $790,724 - $1.03 Million	-297,265 Reduced 78.74%	80,247 $239,000
Q1 2021 May 17, 2021	BUY	$1.98 - $5.36 $747,473 - $2.02 Million	377,512 New	377,512 $1.22 Million
Q2 2020 Aug 14, 2020	SELL	$0.77 - $1.13 $12,447 - $18,266	-16,165 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$0.69 - $1.52 $20,161 - $44,412	-29,219 Reduced 64.38%	16,165 $14,000
Q4 2019 Feb 14, 2020	BUY	$0.88 - $1.29 $15,796 - $23,155	17,950 Added 65.43%	45,384 $44,000
Q3 2019 Nov 14, 2019	SELL	$1.03 - $1.75 $2,633 - $4,474	-2,557 Reduced 8.53%	27,434 $28,000
Q2 2019 Aug 14, 2019	SELL	$1.43 - $1.87 $43,892 - $57,397	-30,694 Reduced 50.58%	29,991 $54,000
Q1 2019 May 15, 2019	SELL	$1.18 - $1.91 $41,420 - $67,044	-35,102 Reduced 36.65%	60,685 $0
Q4 2018 Feb 14, 2019	BUY	$1.01 - $2.78 $60,508 - $166,547	59,909 Added 166.98%	95,787 $113,000
Q3 2018 Nov 13, 2018	BUY	$1.72 - $2.71 $24,711 - $38,934	14,367 Added 66.79%	35,878 $0
Q1 2018 May 11, 2018	BUY	$1.8 - $2.74 $13,212 - $20,111	7,340 Added 51.8%	21,511 $45,000
Q4 2017 Feb 09, 2018	BUY	$1.22 - $3.73 $4,368 - $13,357	3,581 Added 33.81%	14,171 $29,000
Q3 2017 Nov 09, 2017	BUY	$0.94 - $1.35 $9,954 - $14,296	10,590	10,590 $14,000

Others Institutions Holding INFI

# of Institutions

Shares Held

1.26M

Call Options Held

Put Options Held

View Full List

About INFINITY PHARMACEUTICALS, INC.

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

More about INFI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account